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NF-kBPoly(ADP-ribose) polymerase-1 (PARP-1) and its cleavage products regulate cell viability and NF-kB activitywhen
expressed in neurons. PARP-1 cleavage generates a 24 kDa (PARP-124) and an 89 kDa fragment (PARP-189). Com-
pared toWT (PARP-1WT), the expression of an uncleavable PARP-1 (PARP-1UNCL) or of PARP-124 conferred protec-
tion from oxygen/glucose deprivation (OGD) or OGD/restoration of oxygen and glucose (ROG) damage in vitro,
whereas expression of PARP-189 was cytotoxic. Viability experiments were performed in SH-SY5Y, a human neu-
roblastoma cell line, as well as in rat primary cortical neurons. Following OGD, the higher viability in the presence
of PARP-1UNCL or PARP-124 was not accompanied with decreased formation of poly(ADP-riboses) or higher NAD
levels. PARP-1 is a known cofactor for NF-kB, hence we investigated whether PARP-1 cleavage inﬂuences the in-
ﬂammatory response. All PARP-1 constructs mimicked PARP-1WT in regard to induction of NF-kB translocation
into the nucleus and its increased activation during ischemic challenge. However, expression of PARP-189 construct
induced signiﬁcantly higherNF-kB activity than PARP-1WT; and the samewas true for NF-kB-dependent iNOS pro-
moter binding activity. At a protein level, PARP-1UNCL and PARP-124 decreased iNOS (and lower levels of iNOS tran-
script) andCOX-2, and increasedBcl-xL. The increased levels ofNF-kB and iNOS transcriptional activities, seenwith
cytotoxic PARP-189, were accompanied by higher protein expression of COX-2 and iNOS (and higher levels of INOS
transcript) and lower protein expression of Bcl-xL. Taken together, these ﬁndings suggest that PARP-1 cleavage
products may regulate cellular viability and inﬂammatory responses in opposing ways during in vitro models of
“ischemia”.
Published by Elsevier B.V.1. Introduction
Poly(ADP-ribose) polymerase 1 (PARP-1), also known as ARTD1
(diphtheria toxin-like-ADP-ribosyltransferase) [1,2], plays a role in the
inﬂammatory pathogenesis of many central nervous system disorders
including stroke [3–6]. A change in PARP-1 activity has been reported
in ischemia–reperfusion damage involving complex mechanisms that
are not completely understood, including regulation of DNA repair,
cell death, transcription and inﬂammation [7].
Here we investigate a possible involvement of PARP-1, particularly
its cleavage products, in the regulation of cell viability using in vitro
models of ischemia (known as oxygen/glucose deprivation, OGD) or
OGD/restoration of oxygen and glucose (ROG).ase 1; PARylation, poly(ADP-
ose deprivation; 24 kDa PARP-
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.PARP-1 is known to have many functions and among them, two are
well known, namely the detection and repair of DNA single strand
breaks through poly(ADP-ribosyl)ation (PARylation) [8,9], and the reg-
ulation of transcription by coupling with many transcription factors
such as NF-kB [10,11]. PARylation requires PARP-1 C-terminal domain
catalytic activity, consuming NAD, and can inﬂuence NF-kB activity
through direct addition of poly(ADP-riboses) (PARs) on to NF-kB itself
[12,13]. PARP-1/ARTD1 contains an N-terminal DNA-binding domain
(DBD), an automodiﬁcation region, and a C-terminal catalytic domain
[14]. The caspase cleavage site DEVD214 is situated in the DBD within
thenuclear localization signal (NLS) [15]. PARP-1 is known to be cleaved
at the DEVD214 site by activated caspases 3 and 7 [16] leading to the for-
mation of a 24 kDa and an 89 kDa fragment (Fig. 1A). Although the con-
sequences of PARP-1 cleavage aswell as of the effects of its two cleavage
products remain unclear, depending on the intensity and type of stimuli
that induce the cleavage itself, two main results have been reported,
namely (1) the reduction of PARylation during DNA repair processes
and (2) the modiﬁcation of transcription activity of a PARP-1 bound
protein complex that includes NF-kB. Generally, following massive
DNA damage, the appearance of 24 kDa and 89 kDa PARP-1 fragments
iswidely accepted as a hallmark of apoptosis [16]. However, the sugges-
tion that PARP-1 cleavage would reduce PARylation and save the cells
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Fig. 1.Characterization of caspase-resistant PARP-1UNCL. (A) PARP-1WT (top) is cleavedby ac-
tivated caspases at the DEVD214 site. Upon cleavage the two fragments, 24 and 89 kDa, are
produced (middle). PARP-1UNCL cannot be cleaved (bottom). DNA binding domain (DBD),
automodiﬁcation region containing theBRCT, and the catalytic domain are highlighted in yel-
low, green andpink, respectively. ZF = Zinc Finger domains I, II and III, NLS = Nuclear Local-
ization Sequence, BRCT = Breast Cancer Suppressor Protein. (B) Western blots of total cell
extracts showing tet-dependent over expression of PARP-1WT or PARP-1UNCL (left) and
its quantiﬁcation by densitometry (right), n = 9. (C)Western blots showing DEVN214 re-
sistance to caspase-induced cleavage (left) and corresponding density (right). n = 3.
Etop = Etoposide. For B and C, data are expressed as mean ± SD,*p b 0.02.
641P. Castri et al. / Biochimica et Biophysica Acta 1843 (2014) 640–651from excessive energy (NAD+, ATP) depletion still remains [17,18]. An
alternative role for PARP-1 cleavage acting as a regulator of NF-kB
transactivation is being increasingly investigated [10,19–23].
NF-kB is a central cellular module that regulates, among other
things, the inﬂammatory response [24]. The major subtype of NF-kB
consists of a hetero-dimer of subunits p50 and p65, which is kept inac-
tive by the inhibitor of NF-kB protein (IKB) in the cytoplasm.Upon stim-
ulation, IKB is ubiquitinated and degraded allowing NF-kB translocation
to the nucleus where it binds to DNA and activates transcription. It has
been shown in animal models that ischemia activates NF-kB leading to
the inﬂammatory response, and that its inactivation is generally neuro-
protective [25,26]. Reports also indicate that the activation of certain
NF-kB-dependent pro and anti-inﬂammatory/protective genes is regu-
lated by complex mechanisms that are still poorly understood [27].Previous observations suggest that PARP-1 and NF-kB functions are
interconnected in ischemic conditions [28–31]. One more layer of com-
plexity is that not only is PARP-1 a cofactor forNF-kB, but the cleavage of
PARP-1 further inﬂuences NF-kB activity. A few reports have suggested
that PARP-1 cleavage may participate in transactivation of NF-kB in a
pro-inﬂammatory fashion [11,23,32–34]. It is of particular interest that
an uncleavable form of PARP-1 (PARP-1UNCL) (Fig. 1A) in transgenic
mice conferred protection from endotoxic shock, and intestinal and
renal ischemia/reperfusion damage [23].
Therefore, the aim of this study was to shed light on the function-
al role of PARP-1 cleavage at the DEVD site and to investigate the role
of each fragment produced in cell viability and the NF-kB transcrip-
tional response during ischemic stress. Human neuroblastoma cells
(SH-SY5Y) were used in models of “ischemia” (oxygen/glucose dep-
rivation —OGD) to study four variants of PARP-1 (control PARP-1WT
and three experimental variants of PARP-1, PARP-1UNCL, PARP-124
and PARP-189) on (1) cell survival and (2) the transcriptional regula-
tion of NF-kB-dependent proteins. Cell survival studies were extend-
ed in a complimentary model (OGD/ROG) using primary rat cortical
neurons.
We found that the uncleavable PARP-1UNCL aswell as PARP-124were
cytoprotective, and PARP-189 was toxic. This study also suggests that
PARP-1 cleavage or its fragments do not modify cellular levels of PARs
or NAD levels, at least in our OGD model. However, NF-kB activity and
the expression of certain downstream effectors were modulated by
the different forms of PARP-1. Theseﬁndings suggest that PARP-1 cleav-
age may play a role in the regulation of cell viability and NF-kB in re-
sponse to OGD or OGD/ROG.2. Materials and methods
2.1. Cell culture and transfection: SH-SY5Y and primary rat cortical neurons
Human neuroblastoma cells, SH-SY5Y (American Type Culture Col-
lection,Manassas, VA, USA; Cat# CRL-2266), were cultured in Dulbecco's
modiﬁed Eagle's medium (DMEM) supplemented with 10% heat-
inactivated fetal bovine serum, 100 U/ml penicillin, and 100 mg/ml
streptomycin (DMEM complete) in 5% CO2 at 37 °C. Tetracycline (tet)-
inducible stable transfectants were generated as previously described
[35]. In particular, the constructs used were PARP-1WT, PARP-1 UNCL,
PARP-124 and PARP-189. See Section 2.2 “Cloning” for more details.
Lipofectamine RNAimax (Invitrogen) was used to transfect the cells
with siRNA-PARP-1 (Target Sequence: 5′-ACGGTGATCGGTAGCAAC
AAA-3′, FlexiTube, Qiagen) at a concentration of 25 nM. In experiments
with siRNA, tet (1 μg/ml) was added at the same time as the siRNA in
order tominimize theperiod of PARP-1 deprivation. All the experiments
were performed using siRNA-PARP-1 with the exception of viability ex-
periments for cells overexpressing PARP-124 and PARP-189. siRNA-
PARP-1 was not used for viability experiments conducted on primary
cortical neurons from rats (where an effect was seen without the need
of reducing the background from endogenous PARP-1). Control experi-
ments were conducted using scramble siRNA (AllStars Negative Control
siRNA, Qiagen) as negative control.
Primary cortical neuronswere isolated from Sprague–Dawley rats at
2 days of age (P2) and cultured in Neurobasal Medium-A (NB-A) sup-
plemented with B27, as previously reported [35] and plated at a density
of 3.75 × 105 cells/ml. Experiments using cells isolated from rat brains
were conducted in accordance with the Institutional Animal Care and
Use Committee at the National Institute of Health guidelines.
Constructs for PARP-1WT, PARP-1UNCL and PARP-124 were cloned
into a custom made viral vector for Adeno-Associated Viruses (AAVs).
See Section 2.2 “Cloning” for more details. Cortical neurons were trans-
duced 3 days after isolation. At day 4 the medium was replaced and at
day 6, aftermeasuring the transfection efﬁciency, the cells were subject-
ed to OGD for 6 h followed by ROG (15 h).
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Wild type PARP-1 plasmidwas purchased from theHarvard Institute
of Proteomics (plasmid ID HsCD00040600 http://plasmid.med.harvard.
edu/PLASMID/Home.jsp) and the sequence was conﬁrmed.
2.2.1. Cloning PARP-1WT, PARP-1UNCL, PARP-124 and PARP-189 into pcDNA4/
TO vector
Constructs for wild type PARP-1WT, PARP-124 and PARP-189 were
ampliﬁed with appropriate restriction sites by PCR using the PARP-
1WT plasmid as a template. The primer sets used were as follows:
AﬂII(F)-5′-AGCTCTTAAGATGGCGGAGTCTTCGGAT-3′ and XhoI(R)-
5′-ATCACTCGAGTTACCACAGGGAGGTCTT-3′ for PARP-1WT; AﬂII(F)-5′-
AGCTCTTAAGATGGATGGAGTGGATGAAG-3′ and XhoI(R)- 5′-ATCACT
CGAGTTACCACAGGGAGGTCTT-3′ for PARP-189; EcoRI(F)-5′-AGCTGA
ATTCATGGCGGAGTCTTCGGAT-3′ and XbaI(R)-5′-CATCTAGATTATCCAT
CCACCTCATCGC-3′ for PARP-124.
Each PCR ampliﬁed DNA was cloned into pcDNA4/TO vector.
PARP-1 siRNA resistant mutants WT and PARP-1UNCL DEVN214
(GAT → AAT) were generated by using the QuickChange II or Quick
Change Multi Site-directed Mutagenesis Kits (Stratagene, La Jolla, CA;
Cat# 200523) as previously described [23]. Primers for siRNA resistant
WT and PARP-1UNCL were as follows: PARP-1UNCL (F)-5′-GAAAAGGC
GATGAGGTGAATG-3′ and PARP-1UNCL (R)-5′-CACTTCATCCACTCCATT
CACCTCATCGCCTTTTC-3′.
2.2.2. Cloning PARP-1WT, PARP-1UNCL and PARP-124 into a viral vector
suitable for packaging an Adeno-Associated Virus (AAV)
PARP-1WT, PARP-1UNCL and PARP-124 were cloned into a viral vector
using appropriate restriction sites, after ampliﬁcation by PCR. Primers
used for PARP-1WT and PARP-1UNCL were MefI(F)-5′-GTACCAATTGAT
GGCGGAGTCTTCGGATAAG-3′ and SalI(R)-5′-CGACGTGTCGACTTACCA
CAGGGAGGTCTTAA-3′. Primers used for PARP-124 were EcoRI(F)-5′-
AGCTGAATTCATGGCGGAGTCTTCGGAT-3′ and SalI(R)-5′-GTACCCGC
GGTCCATCCACCTCATCGCCTTTTC-3′.
Each PCR ampliﬁed DNA was cloned into the pFBGR plasmid (a
pFastBac™ variant obtained from Dr. Robert Kotin, NIH/NHLBI), a plas-
mid containing two AAV inverted terminal repeats (ITRs) ﬂanking the
CMV promoter and EGFP reporter. The EGFP is separated (not fused)
fromPARP-1 gene by a T2A region that allowsmeasurement of transfec-
tion efﬁciency in addition to the overexpression of the gene of interest.
Finally, the poly(A) tail was replaced with Woodchuck Hepatitis Virus
Posttranscriptional Regulatory Element (WPRE) to enhance transcrip-
tion. DH10Bac cells (Invitrogen) were transformed with donor AAV
plasmids (WT, PARP-1UNCL, or PARP-124) and plated on appropriate se-
lection media [36]. Brieﬂy, PARP-1 constructs containing baculovirus
were added along with a second AAV-6 packaging baculovirus (gener-
ous gift from R. Kotin, NIH) which was chosen because we had found
it to be the most efﬁcient in transducing primary cortical neurons in
our preliminary experiments among AAV-2, AAV-4, AAV-5, AAV-6,
and AAV-8. Titering procedure of the ﬁnal AAV was done according to
previously described methods [36].
2.3. Oxygen and glucose deprivation (OGD), OGD/restoration of oxygen and
glucose (ROG) and cell death assessment
OGD for SH-SY5Y or cortical neurons was performed as de-
scribed previously [35]. The lengths of OGD were 15 h for SH-SY5Y
cells and 6 h for cortical neurons, due to their increased sensitivity
to the exposure. SH-SY5Y cells were assayed immediately after
OGD to evaluate cell viability. In the cortical neurons, the OGD me-
dium (PBS with 2 mM MgCl2 and 1 mM CaCl2) was replaced at the
end of OGD with regular NB-A/B27 (ROG) and viability was assayed
15 h later.
After lifting, cell viability of SH-SY5Ywas assessed by differential nu-
clear staining with Propidium Iodide (PI, live-cell impermeant red DNAdye) and Hoechst 33342 (cell permeant blue DNA dye) followed by
quantitative ﬂow cytometric analysis (FACSVantage SE ﬂow cytometer)
as described previously [37,38]. Due to their fragile nature, cell viability
of cortical neurons was assessed by nuclear staining with PI and
Hoechst 33342 performed directly in the well without lifting and the
cells were counted manually under the ﬂuorescent microscope, as pre-
viously described [35]. Cells were counted as follows: 10 ﬁelds were
counted per sample. Each ﬁeld had at least 200 cells. A total of 2000
cells/sample were counted. Experiments were conducted at least in
triplicate.
Furthermore, as primary neuronal cultures do not readily lend
themselves to prolonged and repeated manipulations, biochemical ex-
periments were performed in the more adaptable neuroblastoma cell
lines.2.4. Western blot analysis
Total cell lysates or cytosol/nuclear fractions from SH-SY5Y cells
were used for Western blot analysis (WB). Total cell lysates were
prepared as described previously [35], and cytosolic or nuclear frac-
tions were prepared following a previously reported protocol [39].
After protein concentrations were determined (BCA assay, Pierce),
all samples were heated with ß-mercaptoethanol and dye
(bromophenyl blue) for 5 min at 95 °C. Forty μg of total cell lysate
and 10 μg of nuclear extract were used for each SDS-PAGE/WB anal-
ysis. The following primary antibodies were used for WB analyses:
anti-PARP-1 (Cell Signaling Technology, Danvers, MA; Cat 9546S),
anti-PARP-1 (N-20) (Santa Cruz Biotechnology, Santa Cruz, CA; Cat
SC1561) to detect the 24 kDa fragment, anti-PARP-1 (C-2-10)
(Biomol, Farmingdale, NY; Cat SA250), anti-PARs (Trevigen, Cat
4335-MC-100-AC), anti-p65 (Santa Cruz Biotechnology, Cat sc-
372), anti-iNOS (Santa Cruz Biotechnology, Cat SC7221), anti-COX2
(Cayman, Cat 160126), anti-Bax (Cell Signaling Technology, Cat
2772), anti-Bcl-xL (Cell Signaling Technology, Cat 2762), and anti-
lamin (Abcam, Cat 16048-100). Signals were detected using a chemi-
luminescent substrate (Millipore) followed by digital imaging (Fluor
Chem camera, Alpha Innotech, San Leandro, CA). The optical density
of each western blot lane was measured using the software
AlphaEaseFC 4.0.0. Data are expressed as percent of increase or de-
crease from control, after normalizing the density of each band by
the density of the respective β-actin (total cell extracts) or lamin
(nuclear extracts).2.5. NAD+/NADH quantiﬁcation
Detection of total NAD (tNAD), NAD+ and NADH, was performed
using the NAD+/NADH quantiﬁcation kit (BioVision, San Francisco,
CA). SH-SY5Y cells over-expressing PARP-1WT, PARP-1UNCL, PARP-124
or PARP-189 were seeded at a density of 7.5 × 105/well in a 6 well
plate. Levels of tNAD were measured before and at the end of each
OGD time period (30 min, 2 h, 6 h, 6 h + ROG 2 h, 6 h + ROG 4 h)
in each group of cells. ROG was done to simulate “reperfusion” and re-
store levels of NAD, the PARP-1 substrate. Data were shown as percent
of increase or decrease as compared to untreated cells expressing
PARP-1WT.2.6. Caspase 3/7 activity assay
PARP-1 siRNA treated SH-SY5Y cells over-expressing PARP-1WT,
PARP-1UNCL, PARP-124 or PARP-189 were transferred in a 96 well plate
and subjected to 6 h OGD. Before and after OGD caspase 3/7 activity
wasmeasured (Apo 3/7 HTS; Cell Technology, Mountain View, CA). Re-
sults were expressed as percent of increase by OGD compared to control
(without OGD) in each cell type.
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SH-SY5Y cells were seeded on chambered coverglass (Thermo Fisher
Scientiﬁc, NY, Cat 155380) using DMEM complete with tet. The following
day themediumwas replacedwith OGDmedium and the cells were sub-
jected toOGD for 10 min. Immunostainingwas carried out using anti-p65
antibody (Santa Cruz Biotechnology, Cat sc-372) as a primary antibody
and Alexa Fluor®488 (Molecular Probes) (in green) coupled goat anti-
rabbit IgG as a second antibody. Nuclear staining (in blue) was per-
formed using a mounting medium with DAPI (Vector Laboratories
Inc., Burlingame, CA). Images were captured with an oil immersion
40× objective on a Zeiss LSM510microscope using LSM Image Software.
2.8. Luciferase reporter assays: NF-kB and iNOS
Neuroblastoma cells expressing PARP-1WT, PARP-1UNCL, PARP-124 or
PARP-189 were seeded in a 96-well plate 24 h before performing trans-
fection for either NF-kB or INOS reporter plasmids. The NF-kB reporter
assay was performed using the Cignal NFκB Reporter Assay Kit
(SABiosciences, QIAGEN, Cat CCS-013L) following the manufacturer's
instructions.
The iNOS reporter assaywas performedusing INOSWT(−1485/+31
NF-kB WT) and INOSmutant (−1485/+31 NF-kB mutant) constructs
[40] (kind gift from DrMark Perrella). The mutant form of the INOS pro-
moter region had beenmutated such that NF-kB could not bind to it. NF-
kB is, therefore, unable to bind to mutant INOS promoter, serving as a
negative control of the NF-kB dependent INOS reporter assay. The INOS
WT and mutant promoter regions in pGL2 vector (original constructs
from Dr. Perrella) were transferred into a pGL4 vector (Promega) to
enhance the ﬁreﬂy signal. These constructs (500 ng/well) were then
co-transfected with renilla pRL-TK vector (100 ng/well) for the normal-
ization of transfection efﬁciency. For both NF-kB and INOS assays, the
measurements of ﬁreﬂy and renilla luciferase activities were performed
at the end of 6 h of OGD using Dual-Glo Luciferase Assay System
(Promega) and a luminometer (Centro LB 960, Berthold, Germany).
Background subtraction and normalization were done for all experi-
ments. NF-kB activity was expressed as percent of increase or decrease
from control (PARP-1WT before OGD).
2.9. RNA analyses by real-time polymerase chain reaction
Total RNA was isolated with the High Pure RNA Isolation kit
(Roche Applied Science, Indianapolis, USA). Total RNA concentration
was measured with NanoDrop 2000 UV–Vis Spectrophotometer
(Thermo Fisher Scientiﬁc, DE, USA). 25 ng of RNA was used for real-
time PCR analyses using the LightCycler LC480 System (Roche Applied
Science, Indianapolis, USA) in a one step reaction using LightCycler
480 RNA Master Hydrolysis Probes. Primer pairs used (Real Time
Ready from Roche Applied Science, Indianapolis, USA) and ampliﬁca-
tion protocol are listed in Supplementary Tables S1 and S2. We exam-
ined the gene expressions of INOS and COX-2 (NF-kB-dependent
genes) which have a kb-site located in their promoter regions. Samples
were tested at least in duplicates. Gene speciﬁc expressionwas normal-
ized to an endogenous control (Actin) and expressed in arbitrary units
relative to the expression in untreated cells. Relative quantiﬁcation
was done using the standard curve method with PCR efﬁciency correc-
tion (E-method) of the LightCycler 480 Software (Roche). All samples
were normalized to actin expression on the same plate. The relative
mRNA level was calculatedwith the second derivative formula that cor-
rects for PCR efﬁciency differences between target and reference gene
[41].
2.10. Statistics
Data are shown as the mean ± SD. Statistical analyses were done by
Student T-test and the number of experiments (n) is indicated in theﬁgure legends. P values of b0.05*, b0.01** and b10−5*** were considered
signiﬁcant.
3. Results
3.1. Mutation from DEVD214 to DEVN214 renders PARP-1 resistant to
caspase cleavage
PARP-1UNCL was made by a point mutation (GAT → AAT) in the
214th codon of PARP-1WT. As a result, the 214th amino acid of
PARP-1WT, an aspartate, was changed to an asparagine (D → N).
This mutation makes PARP-1 uncleavable by activated caspases 3
and 7 (Fig. 1A).
Tet-inducible stable human SH-SY5Y transfectants were generated
with PARP-1WT or PARP-1UNCL. As expected, PARP-1 protein (WT or
UNCL) expression levels in these stable transfectants were signiﬁcantly
higher in the presence of tet (3.03-fold for PARP-1WT and 2.94-fold for
PARP-1UNCL) compared to PARP-1 endogenous levels (cells grownwith-
out tet) (Fig. 1B, left and right panels). To conﬁrm that PARP-1UNCL
would be resistant to caspases, the SH-SY5Y stable transfectants of
PARP-1WT or PARP-1UNCL were grown with tet for 24 h and treated
with 0.1 mM etoposide, a topoisomerase II inhibitor and a well
known apoptosis-inducer, for 15 h. Cells were previously transiently
transfected with siRNA-PARP-1. As shown in Fig. 1C, etoposide treat-
ment caused PARP-1WT cleavage and generated an 89 kDa fragment
(53% of the available full length protein was cleaved) while PARP-1UNCL
was not cleaved as much by the same treatment, leaving the 116 kDa
band mostly intact (only 22% of was cleaved, representing endogenous
PARP-1 cleavage) (n = 3, p b 0.02). These ﬁndings indicate that
the mutation at the DEVD site resulted in an uncleavable PARP-1,
PARP-1UNCL.
3.2. Overexpression of PARP-1UNCL confers protection to SH-SY5Y cells from
OGD-induced cell death
Since PARP-1UNCL knock-in mice were reported to be more resis-
tant to endotoxic shock or renal ischemia/reperfusion compared to
WT [23], we tested whether human SH-SY5Y cells over-expressing
PARP-1UNCL were also more resistant to OGD compared to cells
over-expressing PARP-1WT. Unexpectedly, there was no difference
in viability between cells over-expressing PARP-1WT or PARP-1UNCL
after 15 h OGD. We suspected that endogenous PARP-1 might coun-
teract any possible effect derived from overexpression of PARP-
1UNCL. To test this, endogenous PARP-1 was ﬁrst depleted using
siRNA-PARP-1. As shown in 2A, endogenous PARP-1 was almost
completely depleted as compared to untreated cells as well as to
cells treated with scrambled siRNA. We generated a new set of tet-
inducible stable transfectants which were also siRNA resistant for
PARP-1WT or PARP-1UNCL. Endogenous PARP-1 of these cells was al-
most completely depleted by 4 day-treatment of siRNA, and exoge-
nous forms of PARP-1 were conﬁrmed to be siRNA resistant (Fig. 2B).
By simultaneous administration of siRNA and tet, exogenous PARP-
1WT or PARP-1UNCL were exclusively expressed. Scramble siRNA was
used for negative control (transfected in control cells). When these
cells were challenged with OGD, PARP-1UNCL-expressing cells were sig-
niﬁcantly more resistant compared to control cells (viability:
36.79 ± 4.7 control vs 62.32 ± 7.3; mean ± SD; n = 8; p b 0.01)
(Fig. 2C; D bottom right panel). Additional controls were performed
(data not shown) to make sure that, per se, the overexpression of
PARP-1WT or PARP-1UNCL, siRNA or tet did not affect the viability of
the cells. The results strongly suggest that PARP-1 cleavage or its
cleavage products contribute to OGD-induced cell death. Without
OGD, control cells (treated with siRNA scramble and not subjected
to OGD showed a viability of 83.22 ± 0.67 for PARP-1WT and
80.95 ± 2.32 for PARP-1UNCL (Fig. 2C; D top panels)). That only
cells expressing PARP-1UNCL show a signiﬁcantly higher viability
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Fig. 3. Effects of PARP-1 cleavage products onOGD-induced cell death. (A) Viability of cells
grown without tet (cnt = control), and PARP-189 or PARP-124 over-expressing cells
(tet+) after 15 h OGD. Viable cell numberswere compared to non-tet control cells, calcu-
lated as percentage of control (without tet) cells, and shown as mean ± SD of at least 4
independent experiments (*p b 0.05). (B) Representative Western blots of nuclear frac-
tions showing increased expression of PARP-124 (top) and PARP-189 (bottom). Cells
were treated with siRNA before performing OGD.3.3. SH-SY5Y cells over-expressing PARP-124 show resistance to OGD while
cells over-expressing PARP-189 are more susceptible to cell death
Since PARP-1 cleavage is an event that results in the formation of
two products at a ratio of 1:1, we examined the role of cleavage directly
by using the cells that over-expressed each cleavage product (either
PARP-124 or PARP-189). When these cells were challenged by 15 h
OGD, PARP-124 conferred signiﬁcant protection (18.09% increase in via-
bility) compared to control cells (n = 12) (p b 0.05) (Fig. 3A). By con-
trast, PARP-189 signiﬁcantly decreased their viability, by 30.22%, when
compared to control cells (n = 3) (Fig. 3A). Fig. 3B shows representa-
tive immunoblots of PARP-124 (top panel) or PARP-189 (bottom panel)
expression levels with or without tetracycline. These data indicate
that PARP-1 cleavage products have opposing effects on viability follow-
ing OGD. PARP-124 confers protection while PARP-189 is harmful.
3.4. Primary rat cortical neurons transduced with PARP-124 or PARP-1UNCL
are more resistant to OGD/ROG than neurons transduced with PARP-1WT
Using conventional transfectionmethods, high transfection efﬁcien-
cy of primary cultures of rat cortical neurons is extremely hard to
achieve. To overcome this, we developed a viral transduction method
(see Materials and methods) that yields a transfection efﬁciency of ap-
proximately 60%. Due to their potential to confer protection in SH-
SY5Y cells, we focused our efforts on PARP-1UNCL and PARP-124. AsFig. 2. Only after silencing endogenous PARP-1 does the over-expression of PARP-1UNCL
confer resistance to human SH-SY5Ycells exposed to 15 h OGD. (A)Western blots showing
the depletion of endogenous PARP-1 by siRNA. Samples were total extracts from cells un-
treated (ﬁrst lane), treated for 4 days with scrambled (negative control) (second lane) or
treated with PARP-1 speciﬁc siRNA (third lane). (B) Western blots showing the depletion
of endogenous PARP-1, the overexpression of siRNA resistant PARP-1WT or PARP-1UNCL
and the defective accumulation of the 89 kDa fragment in PARP-1UNCL overexpressing
cells when etoposide was used. (C) Cell viability with or without 15 h OGD in siRNA-
resistant PARP-1WT (white bars) or PARP-1UNCL (black bars) stable transfectants, with
siRNA and tet. Data are shown asmean ± SD of 5 (for PARP-1WT) or 8 (for PARP-1UNCL) in-
dependent experiments (*p b 0.01). (D) Representative plots fromﬂowcytometric analysis
of Hoechst 33342 and PI labeled cells over-expressing PARP-1WT (left) or PARP-1UNCL
(right) (tet +; siRNA+) before and after 15 h OGD. Most of the cells can be seen in the
panel that depicts vital cells in the top panels (cells beforeOGD). A fewer number of apopto-
tic cells can be observed in the plot on the right corresponding to SH-SY5Y cells over-
expressing PARP-1UNCL. V = vital cells, M-Ap = middle apoptosis, L-Ap = late apoptosis,
Vl-Ap = very late apoptosis, EN = early necrosis, LN = late necrosis. Cells were treated
with siRNA before performing OGD.
645P. Castri et al. / Biochimica et Biophysica Acta 1843 (2014) 640–651shown in Fig. 4 (bottom panels and histogram), cortical neurons ex-
pressing PARP-124 showed 51% increase in viability compared to cells
expressing PARP-1WT (PARP-1WT = 100%, PARP-124 = 151% ± 21.29;
mean ± SD; n = 5 T-test, p b 0.05). Furthermore, cells expressing
the uncleavable PARP-1UNCL were 22% more viable compared to WT
expressing cells (PARP-1WT = 100%, PARP-1UNCL = 121.75 ± 12;
mean ± SD; n = 5 T-test, p b 0.05). Control cells (treated with the
various viral constructs, but not challenged with OGD) (Fig. 4 top
panels), all had comparable viabilities (67.52 ± 4.2 for PARP-1WT,
65 ± 6.4 for PARP-124, 66 ± 3.8 for PARP-1UNCL), suggesting that mere
introduction of the virus did not disproportionately affect viability.
These data both corroborate results from SH-SY5Y cells suggesting that
PARP-1 cleavagemay regulate cell viability, and also extend the ﬁndings
to rat primary cultured neurons.
3.5. Changes in tNAD and PARs levels do not correlate with viability of
SH-SY5Y cells over-expressing different forms of PARP-1 after OGD
PARP-1 enzymatic activity requires NAD as a substrate to form
PARs, and it is possible that the observed differences in viability
are due to the depletion/consumption of cellular NAD. Two ap-
proaches were used to assess PARylation: measurements of total
NAD (tNAD) levels, and measurements of global PARs formation.
These assays were performed in SH-SY5Y over-expressing PARP-1WT,
PARP-1UNCL, PARP-124 or PARP-189 untreated and exposed to 30 min,0
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(200 μM for 1 h) was used as a positive control since it is known to in-
duce DNA strand breaks and, as a consequence, PARP-1 activation
(PARylation) that in turn consumes tNAD. Levels of tNAD signiﬁcantly
decreased in each cell group after 6 h OGD when compared to tNAD
levels measured before OGD (Fig. 5A; white vs red bars). It is interesting
to note that the baseline tNAD level for PARP-189 is lower than PARP-1WT,
PARP-1UNCL, or PARP-124 (p b 0.01 vsWT). However, with the sameOGD
or OGD/ROG treatment there was no signiﬁcant difference among cells
expressing the different forms of PARP-1 (Fig. 5A; colored bars). Similar-
ly, levels of tNAD greatly decreased after H2O2 treatment, as expected,
and no difference was found among these groups (Fig. 5A; green bars).
To address the possibility that parallel changes in PARs levels
contributed to thedifferences in viability, PARs formationwas evaluated
at the time periods of 30 min and 6 h OGD, based on a pilot time course
study. A signiﬁcant increase in PARs levels was observed following
30 min OGD for all PARP-1 constructs, except PARP-189 (Fig. 5B). Base-
line PARs levels for PARP-189 were already elevated as compared to the
other three forms of PARP-1, an observation complementing that seen
for tNAD levels (Fig. 5B). In contrast, PARs levels detected after 6 h
OGD were comparable and not signiﬁcantly different across all groups
(PARP-1WT, PARP-1UNCL, PARP-124 or PARP-189) (Fig. 5C).
These ﬁndings suggest that PARylation (PARs formation and tNAD)
may not have a role in the regulation of PARP-1 and NF-kB activity
observed in this system.UNCL PARP-124
UNCL PARP-124
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sistant to OGD/ROG compared toWT. Panels labeled “NoOGD” show representative bright
xpressing cortical neurons before OGD/ROG. Panels labeled “OGD” show representative
ing cortical neurons after 6 h of OGD followed by 15 h of reperfusion (ROG). Cell viability
shows representative examples of a vital cell (diffuse blue nucleus with no PI staining, top
apoptotic/necrotic cell (pyknotic blue nucleus with bright red PI staining, bottom arrow-
A148
98
64
50
36
116
89PARP1
0
100
200
300
PARs
Actin
30 min OGDUntreated
PA
RP
-1
W
T
PA
RP
-1
UN
CL
PA
RP
-1
24
PA
RP
-1
89
PA
RP
-1
W
T
PA
RP
-1
UN
CL
PA
RP
-1
24
PA
RP
-1
89
Untreated
OGD (30 min)
PA
R
yl
at
io
n
%
 o
f i
nc
re
as
e/
de
cr
ea
se
fro
m
 w
t
PA
R
yl
at
io
n
%
 o
f i
nc
re
as
e/
de
cr
ea
se
fro
m
 w
t
B
tN
A
D
 (p
mo
l/6
25
00
 ce
lls
)
PARP-1WT PARP-1UNCL PARP-124 PARP-189
PARP1
+
PARs
116
89
0
40
100
20
60
120
80
Untreated
OGD 30 min140
OGD 2h
OGD 6h
OGD 6h+ROG 2h
OGD 6h+ROG 4h
H2O2
C
116
89
24
148
98
64
50
36
0
100
200
300
6h OGD
OGD 6h
PARP1
PA
RP
-1
W
T
PA
RP
-1
UN
CL
PA
RP
-1
24
PA
RP
-1
89
PA
RP
-1
W
T
PA
RP
-1
UN
CL
PA
RP
-1
24
PA
RP
-1
89
PA
RP
-1
W
T
PA
RP
-1
UN
CL
PA
RP
-1
24
PA
RP
-1
89
PARs
***
*
***
***
*
***
NS
*
* *
Fig. 5. Total NAD consumption and PARs formation levels in SH-SY5Y cells over-expressing PARP-1WT, PARP-1UNCL, PARP-124 or PARP-189 after different time points of OGD and OGD/ROG.
(A) Quantitative analyses of the levels of tNAD. Data are shown as mean ± SD (n = 12). p b 0.05*; p b 10−5***. (B) Relative PARylation levels among cells after 30 min OGD. Quantiﬁ-
cation of Western blot densitometry of n = 3 (top panel); Western blot in the lower panel. (C) Relative PARylation levels among cells after 6 h OGD. Quantiﬁcation of Western blot den-
sitometry of n = 5 (top panel); Western blot in the lower panel. OGD = oxygen and glucose deprivation; ROG = restoration of oxygen and glucose; NS = not signiﬁcant. Cells were
treated with siRNA before performing OGD.
646 P. Castri et al. / Biochimica et Biophysica Acta 1843 (2014) 640–6513.6. OGD or OGD/ROG treatment induces caspase activation and PARP-1
cleavage
The appearance of the 89 kDa fragment has been considered as a
hallmark for apoptosis [16] and the occurrence of PARP-1 cleavage in is-
chemia models has been shown before [42,43]. In our model, the frag-
ment was indeed seen in SH-SY5Y cells subjected to a prolonged OGD(15 h) (Fig. S1 A) and in cortical neurons after 2–4 h OGD followed by
15 h ROG (Fig. S1 C). The lack of the appearance of 89 kDa fragment
in earlier OGD time points (data not shown) might be a reﬂection of
the limit of the Western blot assay sensitivity, since caspases 3 and 7
which are responsible for PARP-1 cleavage were already activated as
early as 6 h OGD (Fig. S1 B). However, no differential activations were
seen among cells over-expressing PARP-1WT, PARP-1UNCL, PARP-124 or
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Fig. 6. OGD induces NF-kB translocation to the nucleus. (A) Primary rat cortical neu-
rons were exposed to OGD for 0, 30, 120 and 240 min. Nuclear levels of NF-kB p65
subunit were analyzed by Western blot (n = 3) (B) The nuclear translocation of
p65 was apparent by 10 min of OGD in human SH-SY5Y cells expressing PARP-1WT,
PARP-1UNCL, PARP-124 or PARP-189. Representative blot is shown. Cells were treated
with siRNA before performing OGD.
647P. Castri et al. / Biochimica et Biophysica Acta 1843 (2014) 640–651PARP-189 at least at this time point; an increase of caspase 3/7 activity
that varied around 30% was observed in all cell types (Fig. S1 B). These
results suggest that the protective effects found in PARP-1UNCL and
PARP-124 cells were from downstream events.
3.7. PARP-1 cleavage and its cleavage products do not inﬂuence nuclear
translocation of NF-kB induced by OGD
Since cell sensitivity to OGD seems not to depend on PARylation, we
next examined the possibility that another function of PARP-1, a cofac-
tor for NF-kB, plays a role in cell viability during OGD. To do so, we ﬁrst
examined the initial step of NF-kB activation, namely p65 (a subunit of
NF-kB) translocation into the nucleus. In primary cortical neurons from
rats, nuclear levels of p65 increase by 30 min after OGD, peak at 2 h and
decrease to baseline by 4 h (Fig. 6 A). While levels of p65 increased in
the nucleus by 2 h in cortical neurons from rats, a corresponding de-
crease in p65 cytoplasmic levels was difﬁcult to observe. However,
IKB-α, the protein that anchors p65 in the cytoplasm, is degraded at
2–4 h of OGD (Fig. S2). Human SH-SY5Y cells showed p65 nuclear
translocationwithin 10 min of OGD in the all of the cell types examined
(e.g. expressing PARP-1WT, PARP-1UNCL, PARP-124 or PARP-189) (Figs. 6B
and S3). From these results it is clear that OGD is indeed a stimulus that
induces NF-kB nuclear translocation, but this action was not affected by
PARP-1 cleavage or cleavage products.
3.8. PARP-1 cleavage appears to be a regulator of NF-kB activity in SH-SY5Y
PARP-1 and NF-kB are known to be part of a larger nuclear
multiprotein complex involved in gene transcription [11,44]. We hy-
pothesized that PARP-1 cleavage products may differentially regulate
activity of NF-kB once it is in the nucleus. To test this hypothesis we
used a NF-kB reporter assay to evaluate global NF-kB activity. OGD in-
duced NF-kB activity comparably in all cell groups except PARP-189
cells, which displayed a signiﬁcant increase (Fig. 7A). We then analyzed
a well known NF-kB-dependent gene, INOS. To study the speciﬁcity of
NF-kB p65 subunit binding to INOS promoter, we used two constructs:
one was WT for INOS promoter region [INOS(−1485/+31 NF-κB
WT)] and the other was mutated at 3 binding sites of NF-κB for INOS
promoter region [INOS(−1485/+31 NF-κB mut)]. The mutant form of
the INOS promoter had been mutated such that NF-kB could not bind
to it. For this reason, it can be used as a negative control to investigate
the dependency of NF-kB activity in INOS reporter assays. OGD in-
creased the levels of p65-dependent INOS transcription in all cell
types. Among them, cells expressing PARP-189 showed a signiﬁcantly
greater increase of INOS transcription than the other PARP-1 isoforms
(Fig. 7B). This increase was speciﬁcally induced by NF-kB since
there was no corresponding increase in the levels of INOS expression
when the INOS mutant construct was used (Fig. 7B), suggesting that
PARP-189 indeed modulates NF-kB activity.
To conﬁrm these data, rt-qPCRwas used. First a time course for OGD
was performed and a peak in expression level for both INOS and COX-2
was identiﬁed at 4 h (Fig. 7C). Next, SH-SY5Y cells overexpressing
PARP-1WT, PARP-1UNCL, PARP-124 or PARP-189 were subjected to 4 h
OGD and the levels of INOS transcript conﬁrmed the data obtained by
the reporter assay (Fig. 7D). In particular, INOSmessage level is signiﬁ-
cantly higher in the cells expressing PARP-189 and signiﬁcantly lower
in PARP-124 expressing cells compared to PARP-1WT expressing cells.
3.9. Cells over-expressing PARP-1UNCL or PARP-124 which are protected
from OGD show a reduced inﬂammatory proﬁle
In order to estimate the scope of the effect of PARP-1 cleavage prod-
ucts, particularly the 89 kDa fragment on NF-kB activity, we chose sev-
eral proteins with NF-kB-dependent expression such as MnSOD, ICAM-
1, c-IAP, MMP-9, iNOS, COX-2, Bax and Bcl-xL and analyzed them in
human SH-SY5Y cells expressing PARP-1WT, PARP-1UNCL, PARP-124 orPARP-189. SH-SY5Y cells were subjected to 6 h OGD and the levels of
the proteins mentioned above were measured by Western blot analy-
ses. Among them, we found the protein expressions of iNOS, COX-2,
Bax and Bcl-xL were inﬂuenced by PARP-1UNCL or PARP-1 products.
The pro-inﬂammatory/harmful protein iNOS (Fig. 8A, white bars)
which is known to have a kb-site located in its promoter, was signiﬁ-
cantly lower in cells over-expressing either PARP-124 or PARP-1UNCL
by 46% and 33%, respectively (n = 3; p b 0.05), compared to WT cells
after 6 h OGD. COX-2 protein levels in these cells were comparable to
WT cells. In contrast, the expression of an anti-apoptotic/protective pro-
tein Bcl-xL was signiﬁcantly higher in these cells (twice as much in
PARP-124 expressing cells compared to PARP-1WT, n = 5, p b 0.05)
(Fig. 8B, light gray). These data support the idea that the protection con-
ferred by the over-expression of PARP-124 and uncleavable PARP-1UNCL
could be mediated, in part, through NF-kB regulation of iNOS (down
regulation), COX-2 (no increase observed) and Bcl-xL (up regulation).
Conversely, cells over-expressing PARP-189, which were very sensitive
to OGD, showed a signiﬁcantly higher level of the pro-inﬂammatory/
harmful proteins iNOS and COX-2 (1.7-fold, n = 3, p b 0.05) and
lower level of Bcl-xL (58% of WT, paired t-test; p b 0.05). Finally, even
if the expression levels of pro-apoptotic protein Bax were not signiﬁ-
cantly different among these cell groups, there is a reduction in its levels
in cells expressing PARP-1UNCL and PARP-124.
4. Discussion
This report sheds light on the functional role of PARP-1 cleavage
products in models of in vitro “ischemia” using OGD in human SH-
SY5Y cells and OGD/ROG in primary rat cortical neurons. To the best
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Fig. 7.NF-kB and iNOS reporter assays. OGD (4 h) induces an increase inNF-kB and iNOS activity in human SH-SY5Y expressing PARP-1WT, PARP-1UNCL, PARP-124 or PARP-189. (A) Though
the increase in NF-kB activity can be observed in all cell groups after OGD, among these cells only PARP-189 induced a signiﬁcantly higher activity compared to PARP-1WT, PARP-1UNCL or
PARP-124. (B)When the construct for INOS promoter usedwasWT for NF-kB binding sites (INOSWT), OGD induced an increase in INOS activity in cells expressing PARP-1WT, PARP-1UNCL,
PARP-124 and PARP-189. Among these cells only PARP-189 showed a signiﬁcant increase in INOS transactivation.When the construct for iNOS promoter used wasmutated for NF-kB bind-
ing sites (INOSmut) none of the cells showed an induction of the signal with OGD, suggesting that PARP-1 acts through NF-KB transactivation. All reporter assay experiments were con-
ducted in the presence of siRNA, in triplicates, repeated at least 3 independent times and conducted at the same time for the different cell lines; p b 0.01. RLUs as F/R = Relative luciferase
units as ﬁreﬂy/renilla. Fig. 7C and D provides quantitative analyses of transcription levels for iNOS and COX-2 during OGD. (C) Levels of iNOS and COX-2 transcripts measured after OGD in
wild type SH-SY5Y cells (time course). (D) Levels of INOS RNA after 4 h OGD in cells overexpressing PARP-1WT, PARP-1UNCL, PARP-124, and PARP-189. Cells were pretreated with siRNA.
Results are expressed as mean ± SD of n = 3.
648 P. Castri et al. / Biochimica et Biophysica Acta 1843 (2014) 640–651of our knowledge, this is the ﬁrst study demonstrating that expression
of the uncleavable PARP-1UNCL confers protection in this model. It is in-
teresting that even though PARP-1UNCL is not present in nature, ourﬁnd-
ings and previous studies [23,45] suggest that PARP-1 cleavage and its
cleavage products regulate functions and control mechanisms related
to cell survival and cell death. Hence, a novel element in this study
was to show differential effects on viability by the 24 kDa and the
89 kDa fragment, products of PARP-1 cleavage.
This study also reports that the overexpression of PARP-124 con-
fers protection from OGD in SH-SY5Y cells as well from OGD/ROG
in cortical neurons, suggesting that this part of the molecule may
be necessary to perform this function. PARP-124 preserves more than
60% of the PARP-1 DNA binding domain; it has been shown that this
fragment may compete with PARP-1WT for DNA binding and reduce
PARylation [17,46–48]. If this were occurring in our studies, one
would expect to see higher levels of NAD and lower levels of PARylation
after OGD compared to WT in cells expressing this fragment. However,
PARP-124 (like PARP-1UNCL) did not change NAD levels and PARylation
after OGD. As cellular apoptosis was also not apparent, we evaluated
the hypothesis that PARP-1 cleavage products might affect NF-kB-
dependent molecular pathways.
It has been shown that PARP-1 can bind to NF-kB [11], and that sub-
sequent PARP-1 cleavage by caspases 3 and 7 could modulate the NF-kB-dependent inﬂammatory response in an apoptosis-independent
event [20,23,45]. We then hypothesized that PARP-1 cleavage could
be an element that ﬁnely tunes NF-kB activity, depending on its binding
to different parts of the PARP-1 molecule (N or C-terminal fragment),
which are produced by the cleavage (hypothetical model in Fig. 9).
Although it is still unclear in our system whether the inﬂuence of
PARP-1 fragments on NF-kB is indirect or occurs via direct interac-
tion, several differences in NF-kB activity and NF-kB-related mole-
cules were seen when the different constructs were expressed in
SH-SY5Y. In our model, OGD induces p65 translocation into the nucleus
in both cell types within 10 min. “Ischemia” in vitro increases NF-kB
global activity in all groups, but no further increase was observed for ei-
ther PARP-1UNCL or PARP-124 overexpressing cells. In contrast, cells ex-
pressing PARP-189 show a signiﬁcant increase in both general NF-kB
activity as well as NF-kB-dependent induction of iNOS. In addition,
cleaved fragments PARP-124 and PARP-189 have opposing actions on
the protein levels of reported NF-kB downstream effectors iNOS (as
well as on increased iNOS transcript levels), COX-2, and Bcl-XL. Col-
lectively, these data suggest that even though there is an increase
in NF-kB activity, this increase could be translated into either an in-
crease or a decrease in molecules usually considered markers of a
more “anti-inﬂammatory” or “pro-inﬂammatory” proﬁle. It should be
noted that, although neuroblastoma cells are not classically considered
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formation of the multiprotein complex between
phenomenon in the literature (see ref).
The orange area in the middle represents a hy
the differential expression of downstream effec
Fig. 9.Hypothetical model of the mechanism of action of PARP-1 and its cleavage products. Gre
mation of themultiprotein complex between PARP-1 and NF-kB (p65+p50) is a known phenom
hypotheticalmechanism thatmight explain the differential expression of downstreameffectors
where PARP-1 acts as its co-modulator,modifyingNF-kB gene transactivation (left side). NF-kB i
PARP-189) is expressed (right side). The ﬁndings in this study suggest that NF-kB increased activ
tuned event perhaps inﬂuenced by co-factors such as PARP-1. PARP-1 and its cleavage produc
PARP-1 molecule is regulating NF-kB activity. After OGD, the expression of PARP-1UNCL or
protective fashion (decreased iNOS and COX-2 protein levels; increased Bcl-xL). The expressio
COX-2 increased; Bcl-xL decreased) show a more pro-inﬂammatory proﬁle (c.). NF-kB = p65
649P. Castri et al. / Biochimica et Biophysica Acta 1843 (2014) 640–651inﬂammatory cells, they have been associated with changes in mole-
cules involved in inﬂammatory pathways [49,50]. We demonstrated
that the overexpression of PARP-1UNCL as well as PARP-124 is associated
with decreases in iNOS and COX-2 proteins, and an upregulation of the
anti-apoptotic/protective protein Bcl-xL. The expression of these proteins
suggests that these anti-inﬂammatory eventsmay be, at least in part, NF-
kB-dependent and are supported by ﬁndings in the literature [51–53]. In
addition, the results of the present study demonstrate that PARP-189, the
other product of PARP-1 cleavage, appears to alter NF-kB transactivation
towards a pro-inﬂammatory proﬁle.
These observations support the idea that an increase of C-terminal
PARP-189 enhances the toxicity of OGD. Previous studies suggested
that the role of PARP-1 cleavage is to protect the cell by inactivation of
PARylation and NAD depletion, and others have reported a loss of
PARP-1 enzymatic activity after cleavage [17]. It is possible that a re-
duction in the levels of NAD combinedwith the increased PARs in the
PARP-189 cells may contribute to an increased energy imbalance,
which could partially explain the increased toxicity seenwhen this con-
struct is expressed. However, several contradictory observations bring
this inference into question. First, levels of NAD are the same across all
the cell lines following OGD (Fig. 5A). If NAD were a factor, one would
expect the levels seen with PARP-189 to be much lower following
OGD. Second, NAD levels in the protected cells (PARP-1UNCL and
PARP-124) are not higher than the control (PARP-1WT). Following
p65 nuclear translocation, we observed a signiﬁcant increase in global
NF-kB activity when compared to PARP-1WT as well as a signiﬁcant in-
crease in NF-kB-dependent iNOS activity. Furthermore, these changest have been investigated in this study. The
 NF-kB (p65+p50) is a known 
pothetical mechanism that might explain
tors of NF-kB and cell viability. 
en areas (left and right) indicate events that have been investigated in this study. The for-
enon in the literature (see Refs. [11,20,56,57]). The orange area in themiddle represents a
of NF-kB and cell viability. Upon stimulationwith OGD,NF-kB translocates into the nucleus
ncreased activity is observedwhen eachof thePARP-1 constructs (PARP-1UNCL, PARP-124 or
ity is not only a quantitative phenomenon during cellular ischemic stress, but also a ﬁnely
ts may be capable of regulating post-translational events depending on which part of the
PARP-124 (a and b) leads to an increased NF-kB activity in a more anti-inﬂammatory/
n of PARP-189 also induces NF-kB transactivation, but its downstream effectors (iNOS and
+ p50; 24 kDa = PARP-124; 89 kDa = PARP-189.
650 P. Castri et al. / Biochimica et Biophysica Acta 1843 (2014) 640–651were accompanied by higher levels of the pro-inﬂammatory/harmful
protein iNOS (as well as its mRNA), COX-2 and the amount of the
anti-apoptotic/protective protein Bcl-xL.
These observations provide renewed impetus for further investiga-
tion of the mechanisms involved in NF-kB regulation —a transcription
factor with well known clinical signiﬁcance. The ﬁndings provide just
one paradigm of the complex protein regulation in which PARP-1 is
just one of the players. However, understanding how the intricate pro-
tein to protein interactomes [44,54,55] are regulated is an important, if
daunting challenge.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2013.12.005.Acknowledgements
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